Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CEBPA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CEBPA Recombinant Protein (WT & p30 Mutant) High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. Suitable for DNA-binding and PPI assays. |
View CEBPA Products |
| Gene Delivery | CEBPA Promise-ORF / Lentivirus Full-length human CEBPA ORF for stable lineage differentiation and overexpression assays. |
View CEBPA Products |
| Benchmark Ab | Anti-CEBPA Recombinant Antibody High-affinity sequence-verified positive control for Western Blot, ChIP, and IHC. |
View CEBPA Products |
| Validator | CEBPA siRNA Set Target-specific knockdown pool for functional validation in myeloid differentiation assays. |
View CEBPA Products |
| Related Target A | TRIB1 (Tribbles Pseudokinase 1) Key adaptor promoting ubiquitin-mediated degradation of CEBPA; therapeutic target for AML. |
View TRIB1 Products |
| Related Target B | RUNX1 (Runt-Related Transcription Factor 1) Synergistic transcription factor in hematopoiesis; frequently co-mutated in myeloid leukemias. |
View RUNX1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing WT (p42) vs. Dominant-Negative (p30) Isoforms | Isoform-specific recombinant proteins strictly verified by Mass Spectrometry and Western Blot. |
| High-throughput Screening for Transcription Factor Activators | Lentiviral vectors with optimized promoters for robust reporter gene assays in hematopoietic cell lines. |
| Lack of Validated Control Antibodies | Recombinant monoclonal benchmark antibodies with consistent batch-to-batch performance. |
| Off-Target Effects in RNA Therapeutics (saRNA/siRNA) | Sequence-verified siRNA pools and mismatch controls for highly specific knockdown verification. |
Live CEBPA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CEBPA (CCAAT/enhancer-binding protein alpha) represents a paradigm shift in both oncology and metabolic disease. Traditionally considered "undruggable" due to its localization as an intracellular bZIP transcription factor, CEBPA is now the center of cutting-edge RNA therapeutics and targeted protein degradation (TPD) strategies.
In acute myeloid leukemia (AML), loss-of-function mutations in CEBPA halt myeloid differentiation, making the restoration of CEBPA activity a prime therapeutic objective. The clinical advancement of small activating RNAs (saRNAs), such as MTL-CEBPA, has demonstrated the feasibility of upregulating this master regulator to reverse immune suppression in the tumor microenvironment (TME) and induce leukemia cell differentiation. Simultaneously, in NASH/MASH and hepatocellular carcinoma (HCC), CEBPA's role in regulating lipid metabolism and systemic inflammation has positioned it as a critical target for metabolic reprogramming.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| saRNA (Small Activating RNA) | MiNA Therapeutics | HCC, Solid Tumors, AML | Upregulation validation (Need high-titer Lentivirus for positive controls & qPCR standards) |
| Small Molecule (TPD / Molecular Glues) | Boehringer Ingelheim, Novartis | AML (CEBPA-mutant) | Protein-protein interaction assays (Need recombinant WT CEBPA & TRIB1 proteins) |
| Gene Therapy / mRNA | Academic/Biotech Consortiums | Severe Congenital Neutropenia | Functional rescue assays (Need sequence-verified CEBPA siRNA and expression vectors) |